Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

Pogeu Mahone

To: Mimbari who wrote (12223)	7/13/2013 12:29:00 PM
From: NTTG	1 Recommendation Read Replies (1) of 13111

You must be joking, have you ever been to the company website before? Read the yellow highlighted target lesion responses for the tables at the bottom of the third column (from the left of course) Here let me help you: CR + PR, stage III subjects = 60% CR + PR, stage IV subjects = 22% CR + PR + SD, stage III subjects = 79% CR + PR + SD stage IV subjects = 33% Do you see in both cases how much smaller the response of stage IV patients is compared to stage III. In the forth column you will see the overall survival of stage IV patients treated with PV-10 compared to stage III patients... simple stuff pvct.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next